Microbubble formulation
A DSPC and DSPG-coated microbubble formulation with perfluorocarbon gas effectively prevents the ABC phenomenon, maintaining ultrasound contrast efficacy through reduced anti-PEG antibody induction and prolonged blood retention.
Patent Information
- Application Number
- JP2020130343
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-07-31
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2040-07-31
AI Technical Summary
Existing microbubble preparations for ultrasound contrast agents suffer from the accelerated blood clearance (ABC) phenomenon, leading to reduced ultrasound contrast effect upon repeated administration due to the induction of anti-PEG antibodies.
A microbubble preparation composed of a lipid coating made of distearoylphosphatidylcholine (DSPC) and distearoylphosphatidylglycerol (DSPG) with perfluoropropane, perfluorobutane, or perfluorohexane gas, designed to avoid the ABC phenomenon by minimizing anti-PEG antibody induction.
The microbubble preparation maintains stable ultrasound contrast performance even upon repeated use, suppressing anti-PEG IgM antibody production and ensuring prolonged blood retention.
Smart Images

Figure 0007582646000001 
Figure 0007582646000002 
Figure 0007582646000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a microbubble preparation capable of avoiding the ABC phenomenon. [Background technology]
[0002] In clinical practice, microbubbles (hereinafter sometimes referred to as MB), which are lipid membranes with gas encapsulated in their outer shell, are used as contrast agents for hemodynamic evaluation during ultrasound examinations. The main contrast agents used in Japan are Levovist (registered trademark) and Sonazoid (registered trademark). Levovist is used for diagnosing cardiovascular angiography, while Sonazoid is used for diagnosing liver cancer and breast tumors by Kupffer cell imaging.
[0003] Many MB preparations used clinically have problems with stability and blood retention. To solve these problems, we have developed a stable MB with high blood retention that contains distearoylphosphatidylglycerol (hereinafter sometimes referred to as DSPG) as its main component (Non-Patent Document 1). That is, DSPC:DSPE-PEG 2000 A microbubble formulation prepared by adding DSPG to a composition based on β-glucose and using a homogenizer in the presence of perfluoropropane gas showed stable contrast. Polyethylene glycol (hereinafter sometimes referred to as PEG)-modified lipids are used in this MB to improve stability.
[0004] However, it has been reported that liposomes containing PEG-modified lipids exhibit accelerated blood clearance (hereinafter sometimes referred to as ABC phenomenon), in which the clearance rate increases significantly with repeated administration compared to the initial administration. That is, it has been reported that when an animal that has been administered a microbubble formulation once is administered the same or a different type of microbubble formulation after a certain period of time, the blood clearance of the microbubble formulation administered the second time is accelerated, and the blood concentration of the microbubble formulation drops sharply (see Non-Patent Documents 2 and 3).
[0005] This ABC phenomenon is caused by anti-PEG antibodies induced by exposure to PEG-containing materials. Recently, it has been reported that the ultrasound contrast effect of PEG-containing MB preparations is shortened when the ABC phenomenon occurs (Non-Patent Document 4). Since the ABC phenomenon affects the ultrasound contrast effect of MB, the development of MB preparations that can avoid the ABC phenomenon is expected to lead to improved diagnostic performance when MB is used repeatedly. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Unga J., et al., J Liposome Res., 29, 368-374(2019). [Non-Patent Document 2] Ishida T., Kiwada H., Int J Pharm., 354, 56-62 (2008). [Non-Patent Document 3] Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC., Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.J Pharmacol Exp Ther.2000 Mar;292(3):1071-9 [Non-Patent Document 4] Fix SM, et al., Ultrasound Med Biol., 44, 1266-1280 (2018). Summary of the Invention [Problem to be solved by the invention]
[0007] The present invention has been made in consideration of these problems, and has an object to provide a microbubble preparation that is less likely to cause the ABC phenomenon even when used repeatedly. [Means for solving the problem]
[0008] The microbubble preparation of the present invention comprises a lipid coating and a gas enclosed in the cavity of the coating, and is capable of avoiding the Accelerated Blood Clearance (ABC) phenomenon. The coating is a lipid composed of distearoylphosphatidylcholine (DSPC) and distearoylphosphatidylglycerol (DSPG), and the gas contains at least one of perfluoropropane, perfluorobutane, perfluoropentane, and perfluorohexane, or a mixed gas thereof. Effect of the Invention
[0009] According to the present invention, a microbubble preparation is obtained which is less likely to cause the ABC phenomenon even when used repeatedly. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 is a diagram outlining the preparation method of PG(PEG)-MB. [Diagram 2] FIG. 1 is a photograph showing the appearance of PG(PEG)-MB after freeze-drying and after reconstitution with water. [Diagram 3] FIG. 1 illustrates the in vitro stability evaluation method for PG(PEG)-MB, in which (A) is a schematic diagram of the experiment and (B) is an ultrasound contrast image of PG(PEG)-MB in contrast mode. [Figure 4] FIG. 1 shows the ultrasound contrast intensity disappearance curve of PG(PEG)-MB in vitro. [Diagram 5]Figures explaining the imaging evaluation by repeated administration of PG(PEG)-MB. (A) is a schematic diagram of the experiment, and (B) is an image of a mouse kidney imaged by ultrasound imaging in B mode and contrast mode. [Figure 6] FIG. 1 is a diagram illustrating ultrasound imaging upon repeated administration of PG(PEG)-MB, in which (A) is the contrast intensity disappearance curve, and (B) is a graph showing the contrast half-life. [Figure 7] FIG. 1 is a diagram outlining a method for inducing anti-PEG IgM antibodies using PG(PEG)-MB. [Figure 8] FIG. 1 is a diagram for explaining an outline of a method for investigating the effect of preadministration of free PEG on ultrasound contrast of PG(PEG)-MB. [Figure 9] FIG. 1 shows the results of measuring anti-PEG IgM antibody titers in mouse plasma, where (A) illustrates the anti-PEG IgM antibody titer after administration of PEG-modified liposomes, and (B) illustrates the anti-PEG IgM antibody titer after administration of PG(PEG)-MB. [Figure 10] FIG. 1 illustrates the effect of preadministration of free PEG on ultrasound contrast of PG(PEG)-MB, in which (A) is the contrast intensity disappearance curve, and (B) is a graph showing the contrast half-life. [Figure 11] FIG. 1 is a diagram for explaining the evaluation of blood retention of PG(PEG)-MB after administration of PEG-modified liposomes, in which (A) is a contrast intensity disappearance curve, and (B) is a graph showing the contrast half-life. [Figure 12] This figure shows the characteristic evaluation of PEG-unmodified MBs, in which (A) is a photograph showing the appearance of each MB, (B) is a diagram explaining the average particle size of each MB, and (C) is a diagram explaining the number concentration of each MB. [Figure 13] FIG. 1 illustrates the in vitro stability evaluation of nonPEG-MB, in which (A) is the contrast intensity disappearance curve, and (B) is a graph showing the contrast half-life. [Figure 14]FIG. 1 illustrates an in vivo evaluation of blood retention of nonPEG-MB, in which (A) is a contrast intensity disappearance curve, and (B) is a graph showing the contrast half-life. [Figure 15] FIG. 1 shows the results of measuring anti-PEG IgM antibody titers in the blood over time after intravenous administration of nonPEG-MB. [Figure 16] FIG. 1 illustrates ultrasound contrast evaluation following repeated administration of nonPEG-MB, in which (A) is the contrast intensity disappearance curve, and (B) is a graph showing the contrast half-life. [Figure 17] FIG. 1 illustrates ultrasound contrast evaluation of nonPEG-MB in the presence of anti-PEG IgM antibody, in which (A) is the contrast intensity disappearance curve, and (B) is a graph showing the contrast half-life. [Figure 18] FIG. 1 is a diagram illustrating the tissue distribution of MB under induction of the ABC phenomenon, in which (A) shows the results of fluorescence observation by IVIS, and (B) illustrates the relative fluorescence intensity of the liver or spleen. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Hereinafter, an embodiment of the present invention will be described in detail with reference to the attached drawings. However, the embodiment is intended to facilitate understanding of the principles of the present invention, and the scope of the present invention is not limited to the embodiment described below. Other embodiments in which a person skilled in the art appropriately replaces the configuration of the embodiment described below are also included in the scope of the present invention.
[0012] 1. Microbubble formulations The present inventors have succeeded in developing a bubble preparation for theranostics, which combines diagnosis and therapy, but there is a demand for avoiding the ABC phenomenon and improving the diagnostic capability when the bubble preparation for theranostics is used repeatedly. The present inventors have found that the ABC phenomenon is involved in the induction of anti-PEG IgM antibodies, and have succeeded in realizing a microbubble preparation that can suppress the antibody titer of anti-PEG IgM antibodies.
[0013] The microbubble formulation according to this embodiment comprises a lipid coating and a gas sealed within the cavity of the coating.
[0014] The coating is a lipid composed of distearoylphosphatidylcholine (DSPC) and distearoylphosphatidylglycerol (DSPG).
[0015] The gas is a perfluorohydrocarbon gas, specifically containing at least one of perfluoropropane, perfluorobutane, perfluoropentane, and perfluorohexane, or a mixed gas. Perfluorohydrocarbon gas can be purchased for medical use in Japan. Perfluoropropane is preferred. It is possible to include other perfluorohydrocarbons, specifically, perfluoromethane, perfluoroethane, perfluoroisooctane, perfluoronormal octane, and sulfur hexafluoride. The pressure of the gas to be filled is, for example, about 0.1 to 1.0 MPa.
[0016] The molar ratio of DSPC and DSPG is not particularly limited, but can be set as a molar ratio in which DSPG is included more than DSPC, specifically, any combination can be selected from 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.0 to set as a molar ratio in which DSPG is included more than DSPC, and preferably, DSPC and DSPG can be formed at a molar ratio of 9:16 to 3:7, and preferably, DSPC and DSPG can be formed at a molar ratio of 1:2. That is, DSPG / (DSPC+DSPG) can be formed at a molar ratio of 64% to 70%, and preferably, DSPG / (DSPC+DSPG) is formed at a molar ratio of 67%.
[0017] The microbubble preparation of the present invention is a microbubble in which gas is encapsulated in a lipid membrane, and exists in liquid as a foam having a diameter of 10 nm to 5 μm. The diameter of the microbubble preparation is measured, for example, by dynamic light scattering.
[0018] The coating is a lipid consisting of DSPC and DSPG, but it is also possible to further include the lipids shown below. Specifically, phosphatidylethanolamines such as dimyristoyl-phosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), dioleylphosphatidylethanolamine (DOPE), distearoylphosphatidylethanolamine (DSPE), diarachidoylphosphatidylethanolamine (DAPE) or dilinoleylphosphatidylethanolamine (DLPE); dilauroyl-phosphatidylcholine (DLPC), dimyristoyl - phosphatidylcholines such as dipalmitoyl-phosphatidylcholine (DMPC), dipalmitoyl-phosphatidylcholine (DPPC), diarachidoyl-phosphatidylcholine (DAPC) or dioleyl-phosphatidylcholine (DOPC); phosphatidylserine such as dimyristoylphosphatidylserine (DMPS), diarachidoylphosphatidylserine (DAPS), dipalmitoylphosphatidylserine (DPPS), distearoylphosphatidylserine (DSPS) or dioleylphosphatidylserine (DOPS); phosphatidic acid derivatives such as dipalmitoyl phosphatidic acid (DPPA), dimyristoyl phosphatidic acid (DMPA), distearoyl phosphatidic acid (DSPA), diarachidoyl phosphatidic acid (DAPA) and their alkali metal salts; dimyristoyl phosphatidylglycerol (DMPG) and its alkali metal salts, dipalmitoyl phosphatidylglycerol (DPPG) and its alkali metal salts, distearoyl phosphatidylglycerol (DSPG) and its alkali metal salts. Examples of suitable phosphatidylglycerols include potassium metal salts, phosphatidylglycerols such as dioleyl-phosphatidylglycerol (DOPG), and phosphatidylinositols such as dilauroylphosphatidylinositol (DLPI), diarachidoylphosphatidylinositol (DAPI), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), and dioleylphosphatidylinositol (DOPI).
[0019] The lipid surface of the coating may be modified with a ligand for target cells, target tissues, or target lesions. Examples of the ligand include arginine-glycine-aspartic acid (RGD) sequence peptides and Sigma Protein as ligands for thrombi, and transferrin, folic acid, hyaluronic acid, galactose, or mannose as ligands for cancer cells. Monoclonal or polyclonal antibodies can also be used as ligands. RGD peptides are preferred, and RGD peptides have the function of specifically binding to cell adhesion factors present on specific cells or thrombi. Therefore, by modifying the lipid surface of the coating with RGD peptides, it becomes possible to further facilitate visualization of thrombi.
[0020] Other substances may be added to the coating as needed, for example, membrane stabilizers such as sitosterol, cholesterol, dihydrocholesterol, cholesterol esters, phytosterol, stigmasterol, campesterol, cholestanol, lanosterol, 1-O-sterol glucoside, 1-O-sterol maltoside, and mixtures thereof.
[0021] It is also possible to encapsulate or surface-adsorb drugs in the coating of the microbubble formulation for theranostics according to the present invention. The drug is preferably a drug whose blood concentration is desired to be maintained for a long period of time or a drug that needs to be administered with the intention of targeting a specific disease site or cell. The drug is not particularly limited, but examples thereof include anticancer drugs, oncolytic viruses, antibiotics, antiasthmatic drugs, antithrombotic drugs, antiprotozoal drugs, immunostimulants, peptide drugs, and antiviral drugs.
[0022] The anticancer drug is not particularly limited, but examples thereof include doxorubicin, cisplatin, mitomycin, bleomycin, 5-fluorouracil, methotrexate, nitrogen mustard, busulfan, oxaliplatin, taxol, camptothecin, etc. Oncolytic viruses include oncolytic reovirus, oncolytic adenovirus, oncolytic measles virus, oncolytic herpes simplex virus, oncolytic Newcastle disease virus, oncolytic cowpox virus, oncolytic mumps virus, oncolytic coxsackie virus, oncolytic vaccinia virus, etc. Antibiotics include sulfazene, gentamicin, streptomycin, etc. Antiasthmatic drugs include theophylline, etc. Antithrombotic drugs include tPA, heparin, low molecular weight heparin, urokinase, thrombomodulin, streptokinase, etc. Antiprotozoal drugs include meglumine antimonate, etc. Examples of immunostimulants include muramyl peptides, etc. Examples of peptide drugs include natural or recombinant α-, β-, and γ-interferon, interleukins, superoxide desmutase, peptides for vaccines, antigens, etc. Other examples of drugs include arteriosclerosis treatment drugs such as prostaglandins, NF kappa B for arterial occlusion and Virtua's disease, decoys, etc.
[0023] In addition to drugs, genes can also be encapsulated or adsorbed on the surface of microbubbles for theranostics. Examples of genes include DNA, RNA, antisense DNA, siRNA, decoys, therapeutic oligonucleotides, and viral vectors for gene therapy.
[0024] 2.<Production method of microbubble formulation> The microbubble formulation of the present invention can be prepared by dissolving a lipid suspension in an organic solvent, removing the organic solvent under reduced pressure to prepare a lipid thin film, adding a phosphate buffer to the lipid thin film to hydrate it, and shaking at a constant temperature to form liposomes. The prepared liposomes can be stirred at high speed using a homogenizer in the presence of a perfluorohydrocarbon.
[0025] 3.<Lyophilized powder> The microbubble formulation of the present invention can be freeze-dried to enable long-term storage by freeze-drying a suspension of the microbubble formulation of the present invention in a solution of a carbohydrate such as trehalose or sucrose.
[0026] It is also possible to add a freeze-drying additive for cryoprotection and / or dispersion protection during freeze-drying. Examples of the freeze-drying additive include amino acids such as glycine, sugars such as mannitol, maltose, glucose, lactose, inulin, sucrose, trehalose, and cyclodextrin, polysaccharides such as dextran and chitosan, and polyoxyalkylene glycols such as polyethylene glycol.
[0027] This freeze-dried powder can be stored for a long period of time of at least three months, and can be reconstituted with water for injection and a perfluorohydrocarbon gas such as the above-mentioned perfluoropropane for use.
[0028] 4.<How to use microbubble preparations (TB)> When the microbubble formulation of the present invention is used for theranostics, for example, the microbubble formulation of the present invention is used as follows: a suspension of the microbubble formulation of the present invention suspended in water for injection is introduced into a target tissue, which is not particularly limited and may be, for example, a cancer tissue.
[0029] Next, diagnostic ultrasound of a first frequency is applied to the target tissue to perform diagnosis by contrast of the target tissue. The first frequency is, for example, 3 MHz to 20 MHz. The application of the first frequency causes the microstreaming phenomenon. That is, the nanobubbles repeatedly expand and contract due to the sound pressure intensity of the ultrasound, causing localized vibration.
[0030] Next, the target tissue is treated by cavitation by applying low-intensity ultrasound of a second frequency to the target tissue. The second frequency is, for example, 0.5 MHz to 3.0 MHz. The cavitation phenomenon is a phenomenon in which nanobubbles release a large pressure when they collapse, generating a jet flow.
[0031] By applying diagnostic ultrasound of the first frequency to the target tissue, it becomes possible to image the target tissue, and imaging means that by irradiating the target tissue with low-intensity ultrasound or LOFU of the second frequency, treatment by cavitation becomes possible. Furthermore, since the microbubble preparation of the present invention can suppress the ABC phenomenon, it can accurately maintain its diagnostic ability even when used repeatedly. EXAMPLES
[0032] 1. PG(PEG)-MB 1-1. Preparation of PG(PEG)-MB DSPC:DSPG:DSPE-PEG(2k)-OMe = 1:2:0.33 (molar ratio) was dissolved in an organic solvent mixture (chloroform:methanol:10% ammonia water:MilliQ = 65:35:4:4), and the organic solvent was removed under reduced pressure using a rotary evaporator to prepare a lipid thin film. The lipid thin film was then placed in a desiccator overnight under reduced pressure to completely remove the organic solvent. 100 mM phosphate buffer (pH 7.4) was added to this lipid thin film for hydration. After hydration, liposomes were prepared by constant temperature shaking (65°C, 30 minutes, 160 rpm). 20 mL of the prepared 1 mM liposomes was added to a 50 mL Falcon tube, and C 3 F 8 PG(PEG)-MB was prepared by high-speed stirring (15,000 rpm, 5 min) using a homogenizer in the presence of 0.1% glycerol (Figure 1). 1 mL of the prepared PG(PEG)-MB and 18% sucrose solution, which acts as a protectant during lyophilization, were added to a 5 mL vial in a 1:1 ratio, and lyophilized (-35°C; 1 hour, -20°C; 72 hours, +20°C; 40 hours). The lyophilized product (Figure 2) was dissolved in 2 mL of MilliQ and diluted with PBS before use in the experiment.
[0033] 1-2. Measurement method of MB size and number concentration using the Coulter counter method The prepared PG(PEG)-MB (10 μL) was added to 50 mL of ISOTON in a glass beaker, and the average particle size and number concentration were measured using a precision particle size distribution measuring device (Multisizer3) by the Coulter counter method.
[0034] 1-3.In vitro evaluation of the stability of PG(PEG)-MB In order to reduce noise during imaging, 500 mL of degassed PBS (37°C, under stirring) was poured into a beaker equipped with an ultrasonic acoustic absorbing tile, and PG(PEG)-MB (1 × 10 6 The contrast images were then analyzed for brightness using image processing software (ImageJ), and the relative brightness was calculated. The relative brightness was calculated from the maximum brightness using the following formula:
[0035] Relative brightness = measured brightness / maximum brightness x 100 (%) The time when the relative brightness reached 50% was calculated as the half-life of the contrast brightness (contrast half-life).The relative brightness was averaged every second for each measurement, and the disappearance curve of the relative brightness was plotted.
[0036] 1-4.In vivo evaluation method for blood retention of PG(PEG)-MB The hair on the back of a ddY mouse (female, 6 weeks old) was removed, and PG(PEG)-MB (0.25 × 10 7PG(PEG)-MB (0.25 × 10 pieces / mouse) was administered intravenously. After administration of PG(PEG)-MB, the blood retention of each MB was evaluated using the change in ultrasound contrast brightness in the kidney as an index using the contrast mode (irradiation conditions: DR = 72 dB, AO = 70%, MI value = 0.2, Gain = 1 dB) of an ultrasound imaging device (LOGIQE9). The ultrasound images were subjected to brightness analysis using ImageJ, and the contrast half-life was calculated. In addition, PG(PEG)-MB (0.25 × 10 pieces / mouse) was administered intravenously 7 days after the initial administration of PG(PEG)-MB. 7 The antibody was then re-administered (100 μg / mouse) to evaluate blood retention in the same manner, and the imaging half-life was compared.
[0037] 1-5.Characteristics evaluation First, the characteristics of the PG(PEG)-MB prepared in this study were evaluated. As a result, the average particle size of PG(PEG)-MB was 2.16±0.06 μm, and the average particle number concentration at the time of preparation was 1.3±0.3(×10 9 The mean particle size of the existing ultrasound contrast agent Sonazoid was 2-3 μm according to the interview form, and the particle size of PG(PEG)-MB in this study was shown to be almost the same as that of Sonazoid. Furthermore, ultrasound contrast imaging of PG(PEG)-MB in vitro showed that the contrast brightness of PG(PEG)-MB decreased over time. The half-life of PG(PEG)-MB was calculated, and the mean contrast half-life was 124.3 ± 25.4 seconds (Figure 4).
[0038] 1-6. Results of the study Next, to examine the ABC phenomenon of this PG(PEG)-MB, we administered PG(PEG)-MB to mice and then re-administered PG(PEG)-MB 7 days later to examine the transition of ultrasound contrast intensity in the mouse kidney (Fig. 5). The kidney is suitable for observation with ultrasound contrast because it has a large blood flow and is close to the epidermis, and was selected as the observation organ for this study. The contrast half-life of PG(PEG)-MB was calculated, and the ultrasound contrast intensity disappeared earlier in the mice administered the second time compared to the first administration, and the contrast half-life was significantly shortened (Fig. 6). This revealed that PG(PEG)-MB induces the ABC phenomenon. It was concerned that the change in the contrast half-life of MB with repeated administration may be an obstacle when re-examining the same patient in clinical practice. Therefore, it was considered necessary to develop an MB that can avoid the ABC phenomenon. In addition, previous reports have shown that the induction of anti-PEG IgM antibodies is the cause of the ABC phenomenon in the repeated administration of PEG-modified liposomes and PEG-modified MB. This study confirmed the induction of the ABC phenomenon by PG(PEG)-MB, suggesting that the induction of anti-PEG IgM antibodies may also be the cause of the ABC phenomenon in PG(PEG)-MB.
[0039] 2. Involvement of anti-PEG IgM antibodies in the induction of the ABC phenomenon 2-1. Preparation method of PEG-modified liposomes EggPC:Cholesterol:DSPE-PEG(2k)-OMe = 1.85:1:0.15 (molar ratio) was dissolved in chloroform, and the organic solvent was removed under reduced pressure using a rotary evaporator to prepare a lipid thin film. The lipid thin film was then decompressed overnight in a desiccator to completely remove the organic solvent. 20 mL of 25 mM HEPES buffer (0.14 MNaCl, pH 7.4) was added to this lipid thin film for hydration. After hydration, the mixture was shaken at a constant temperature (65°C, 30 minutes, 160 rpm) and sonicated for 10 minutes using a bath-type sonicator. The particle size was then adjusted using an extruder (membrane pore size: 400 nm x 3 times, 200 nm x 15 times, 100 nm x 10 times, 80 nm x 3 times), and filtered through a 450 nm filter to obtain a PEG-modified liposome suspension. The average particle size of the prepared PEG-modified liposomes was measured using a particle size analyzer (Zetasizer Nano-ZS) by dynamic light scattering.
[0040] 2-2. Method for inducing anti-PEG IgM antibodies using PEG-modified liposomes PEG-modified liposomes (EggPC: 0.1 μmol / kg) were administered intravenously to ddY mice (female, 6 weeks old), and blood was collected using a heparin-treated capillary on days 0, 3, 5, 7, 10, and 14 after administration. The collected blood was centrifuged (3400 rpm, 30 min) to collect plasma, and the antibody titer of anti-PEGIgM antibody was evaluated by ELISA using DSPE-PEG(2k)-OMe as the solid phase, diluted mouse plasma as the primary antibody, GOAT anti-MOUSE IgM HRP conjugate (0.1 μg / mL) as the secondary antibody, and TMB as the coloring substrate. The antibody titer was defined as the common logarithm with the base 2 of the maximum dilution ratio at which the absorbance (450 nm) was 0.1 or more.
[0041] 2-3. Method for inducing anti-PEG IgM antibodies using PG(PEG)-MB ddY mice (female, 6 weeks old) were injected with PG(PEG)-MB (0.25 × 10 7PG(PEG)-MB was administered intravenously to each mouse (100 mg / mouse), and blood was collected on days 0, 3, 5, 7, 10, and 14 after administration (Figure 7). The collected blood was centrifuged (3400 rpm, 30 min) to collect plasma, and the antibody titer of anti-PEGIgM antibody was evaluated by ELISA, similar to that used in the experiment on anti-PEGIgM antibody induction by PEG-modified liposomes.
[0042] 2-4. Method for investigating the effect of pre-administration of free PEG on ultrasound contrast of PG(PEG)-MB ddY mice (female, 6 weeks old) were injected with PG(PEG)-MB (0.25 × 10 7 PEG-20k (120 mg / mouse) was administered intravenously to the mice 7 days after administration. PG(PEG)-MB (0.25 × 10 7 After PG(PEG)-MB administration, the effect of free PEG administration on the half-life of PG(PEG)-MB under ABC phenomenon induction was evaluated using an ultrasound imaging device (LOGIQE9) (irradiation conditions: DR=72dB, AO=70%, MI value=0.2, Gain=1dB) to measure the change in ultrasound contrast brightness in the kidney.
[0043] 2-5. Results of the study In this example, we considered using the induction of anti-PEGIgM antibodies by administration of PEG-modified liposomes as a positive control for the study of anti-PEGIgM antibody induction by administration of PG(PEG)-MB. Therefore, we first examined the appropriateness of PEG-modified liposomes as a positive control in the above-mentioned experiment. The average particle size of the PEG-modified liposomes prepared by the method of this study was 73.77 ± 3.71 nm (n = 3). PEG-modified liposomes were administered to mice, blood was sampled daily, and the anti-PEGIgM antibody titer in plasma was examined. As a result, a significant increase in anti-PEGIgM antibody titer was observed 3 days after administration of PEG-modified liposomes, and the high antibody titer continued for 14 days after administration. Therefore, PEG-modified liposomes were considered to be appropriate as a positive control for evaluating PG(PEG)-MB. Next, we examined the induction of anti-PEGIgM antibodies in mice administered with PG(PEG)-MB. As a result, a significant increase in the anti-PEGIgM antibody titer in plasma was observed from the third day after PG(PEG)-MB administration onwards, and the high level continued for 14 days after administration (Figure 9). This increase in anti-PEGIgM antibody titer peaked on the seventh day after PEG-modified MB administration. It was revealed that PG(PEG)-MB administration also induced the production of anti-PEGIgM antibodies, similar to PEG-modified liposome administration. As the production of anti-PEGIgM antibodies was confirmed with PG(PEG)-MB administration, it was considered that the cause of the ABC phenomenon of PG(PEG)-MB was the induction of anti-PEGIgM antibodies. Therefore, in order to clarify the involvement of anti-PEGIgM antibodies in the ABC phenomenon after PG(PEG)-MB administration, a competitive inhibition experiment using free PEG was performed. Free PEG was administered at 120 mg / mouse. When mice were administered PG(PEG)-MB to induce anti-PEGIgM antibodies, they were then administered free PEG and then re-administered with PG(PEG)-MB. As a result, the imaging half-life of PG(PEG)-MB was restored to the same level as that of the first administration (Figure 10). This demonstrated that administration of free PEG eliminated the ABC phenomenon. This was presumably because administration of free PEG competitively inhibited the anti-PEGIgM antibodies that would have otherwise bound to PG(PEG)-MB, preventing opsonization of PG(PEG)-MB.It is believed that the avoidance of opsonization of PG(PEG)-MB leads to the suppression of its uptake in the liver and spleen, and the contrast half-life is equivalent to that of the first administration.These results suggest that the cause of the ABC phenomenon observed with the re-administration of PG(PEG)-MB is anti-PEG IgM antibodies.
[0044] 3. Study on the cross-reactivity of the ABC phenomenon by anti-PEG antibodies 3-1. Preparation method of PEG-modified liposomes PEG-modified liposomes were prepared in the same manner as described above.
[0045] 3-2. Method for evaluating blood retention of PG(PEG)-MB after administration of PEG-modified liposomes PEG-modified liposomes (EggPC: 0.1 μmol / kg) were intravenously administered to ddY mice (female, 6 weeks old). After 7 days, the hair on the back was removed, and PG(PEG)-MB (0.25 × 10 7 After administration of PG(PEG)-MB, the mice were imaged using an ultrasound imaging device (LOGIQE9) in the same manner as described above, and the imaging half-life was calculated.
[0046] 3-3. Results of the study The effect of PG(PEG)-MB on ultrasound imaging was examined when PEG-modified liposomes were administered to mice in which anti-PEGIgM antibodies were induced. As a result, a significant shortening of the ultrasound imaging half-life was observed when PG(PEG)-MB was administered after PEG-modified liposomes compared to PG(PEG)-MB administration to untreated mice (Figure 11). This demonstrated that the anti-PEGIgM antibodies induced by administration of PEG-modified liposomes are also involved in the ABC phenomenon of PG(PEG)-MB. In this way, it was shown that the induced anti-PEGIgM antibodies have cross-reactivity beyond the types of PEGylated preparations. The cross-reactivity of anti-PEGIgM antibodies observed in this example may be a problem in clinical practice, and it is considered necessary to take measures to avoid the influence of anti-PEGIgM antibodies.
[0047] 4. Development of non-PEG-modified microbubbles 4-1. Preparation of non-PEG-MB Each lipid suspension (DSPC:DSPG = 2:1, 1:1, 1:2, 1:3, 1:4 and DSPG 100% (molar ratio)) was dissolved in an organic solvent mixture (chloroform:methanol:10% ammonia water:MilliQ = 65:35:4:4), and the organic solvent was removed under reduced pressure using a rotary evaporator to prepare a lipid thin film. The lipid thin film was then placed in a desiccator overnight under reduced pressure to completely remove the organic solvent. 100 mM phosphate buffer (pH 7.4) was added to this lipid thin film for hydration. After hydration, the lipid thin film was shaken at a constant temperature (65°C, 30 minutes, 160 rpm) to prepare liposomes. 20 mL of the prepared liposomes (lipid concentration 1 mM) were added to a 50 mL tube, and C 3 F 8 Non-PEG-MB was prepared by high-speed stirring (15,000 rpm, 5 min) using a homogenizer in the presence of 0.1% ethanol. The non-PEG-MB and 18% sucrose solution, which acts as a protectant for lyophilization, were added in a 1:1 ratio to a 5 mL vial and lyophilized (-35°C; 1 hour, -20°C; 72 hours, +20°C; 40 hours). The lyophilized product was dissolved in 2 mL of MilliQ and diluted with PBS before use in the experiment.
[0048] 4-2. Measurement method for size and number concentration The size and number concentration of the nonPEG-MBs produced were measured using the Coulter counter method described above.
[0049] 4-3.In vitro stability evaluation method of nonPEG-MB In order to reduce noise during imaging, 500 mL of degassed PBS (37°C, under stirring) was poured into a beaker equipped with an ultrasonic acoustic absorbing tile, and nonPEG-MB (1 × 10 6 The contrast images were analyzed for brightness using ImageJ, and the relative brightness was calculated using the same method as described above.
[0050] 4-4.In vivo evaluation method for blood retention of nonPEG-MB The hair on the back of ddY mice (female, 6 weeks old) was removed, and nonPEG-MB (0.25 × 10 7 After administration of each nonPEG-MB, imaging was performed using an ultrasound imaging device (LOGIQE9) in the same manner as described above, and the imaging half-life was calculated.
[0051] 4-5. Results of the study When MBs were prepared with shell lipid compositions of DSPC:DSPG = 0:1, 1:4, 1:3, 1:2, 1:1 or 2:1 (molar ratio), all of them were milky and had a cloudy appearance, and MBs were formed with all of these compositions (Fig. 12(A)). In addition, the particle size of each MB was measured, and the average particle size of all particles was 5 μm or less (Fig. 12(B)). The number concentration was the highest for PG(PEG)-MB (Fig. 12(C)). The reason for the high number concentration in MBs using PEG-modified lipids was thought to be that the number of MBs prepared increased due to the surfactant effect of the PEG-modified lipids. In any case, the number concentration at the time of preparation was thought to be of no major concern, since MBs were administered to the body in the form of a combined number of MBs.
[0052] In terms of relative brightness, MB with a shell lipid composition of DSPC:DSPG = 1:2 was almost the same as PG(PEG)-MB (Figure 13(A)). In vitro ultrasound imaging showed that the contrast half-life was significantly shorter in shell lipid compositions of DSPC:DSPG = 2:1, 1:1, 1:3, 1:4, and 100% DSPG compared to PG(PEG)-MB (Figure 13(B)). The shell lipid composition of DSPC:DSPG = 1:2 showed a contrast half-life that was not significantly different from that of PG(PEG)-MB. In addition, the shortening of the contrast half-life was smaller in the 1:4 and 100% DSPG compositions compared to the 2:1, 1:1, and 1:3 compositions, suggesting that the composition ratio that increases stability may not be unimodal. However, even when DSPG was 100%, the contrast half-life was significantly longer in the DSPC:DSPG=1:2 composition, which revealed that DSPC:DSPG=1:2 is the optimal composition for the outer shell lipid of MBs that do not use PEG from the viewpoint of stability (Figure 13(B)). It was considered that the steric congestion of PC and PG, which is the lipid monolayer of the MB outer shell, was most effectively alleviated in the DSPC:DSPG=1:2 composition, which led to the stabilization of the MBs.
[0053] Next, we investigated the in vivo imaging half-life of non-PEG-MB with each composition, and found that the blood retention was longer when the outer shell lipid composition was DSPC:DSPG=1:2 (Figure 14). No significant difference was observed in particle size between the outer shell lipid compositions from which PEG was removed. Therefore, it was thought that the improvement in blood retention was mainly due to the improved stability of the MB itself due to the stabilization of the membrane, rather than the particle size.
[0054] 5. Induction of anti-PEG IgM antibodies by non-PEG-modified microbubbles 5-1.Method for measuring anti-PEG IgM antibody titers in blood after intravenous administration of nonPEG-MB A ddY mouse (female, 6 weeks old) was administered non-PEG-MB (0.25 × 10 7PEG-MB was administered intravenously to each mouse (1000 cells / mouse), and blood was collected on days 0, 3, 5, 7, 10, and 14 after administration of nonPEG-MB. The collected blood was centrifuged (3400 rpm, 30 minutes) to collect plasma, and the antibody titer of anti-PEG IgM antibody in the blood was evaluated by ELISA as described above.
[0055] 5-2. Results of the study After administration of nonPEG-MB, blood samples were taken at regular intervals, and anti-PEGIgM antibody titers were evaluated by ELISA. As a result, the anti-PEGIgM antibody titers in the nonPEG-MB administration group were significantly lower than those in the positive control PG(PEG)-MB administration group (P<0.01, Dunnett's test, vs Day 0, 3, 5, 7, 10, 14). However, the nonPEG-MB administration group showed a slight increase in antibody titers compared to the untreated group (Figure 15). Since nonPEG-MB does not contain PEG, this increase in antibody titers was presumed to be due to the induction of nonspecific antibodies against DSPE-PEG(2k)-OMe immobilized on the plate. In any case, the antibody titers were not as high as those observed after administration of the positive control PG(PEG)-MB, and the serum after nonPEG-MB administration was significantly lower than the positive control at all time points. Therefore, it was suggested that the induction of anti-PEGIgM antibodies by nonPEG-MB was weak, and that its antigenicity was reduced compared to PG(PEG)-MB.
[0056] 6.Ultrasound imaging of unmodified PEG microbubbles 6-1.Ultrasound contrast evaluation method for repeated administration of nonPEG-MB The hair on the back of a ddY mouse (female, 6 weeks old) was removed, and nonPEG-MB (0.25 × 10 7 After administration of nonPEG-MB, the mice were imaged using an ultrasound imaging device (LOGIQE9) in the same manner as described above, and the half-life of the imaging was calculated. 7 The antibody was then re-administered to each mouse (100 μg / mouse) and blood retention was evaluated in the same manner.
[0057] 6-2. Ultrasound contrast evaluation method for non-PEG-MB in the presence of anti-PEG antibody The hair on the back of a ddY mouse (female, 6 weeks old) was removed, and PG(PEG)-MB (0.25 × 10 7 Seven days later, nonPEG-MB was administered, and imaging was performed using an ultrasound imaging device (LOGIQE9) in the same manner as above, and the imaging half-life was calculated.
[0058] 6-3. Results of the study When we investigated the induction of the ABC phenomenon by nonPEG-MB, there was no significant difference in the imaging half-life even when nonPEG-MB was administered repeatedly (Figure 16). This suggested that nonPEG-MB does not induce the ABC phenomenon. Furthermore, when nonPEG-MB was administered after PG(PEG)-MB, there was no significant difference in the imaging half-life even in mice in which anti-PEGIgM antibodies were thought to be induced (Figure 17). Therefore, it was revealed that nonPEG-MB is an MB that is not affected by existing anti-PEGIgM antibodies. These results demonstrated that nonPEG-MB is a novel MB that can avoid the ABC phenomenon by satisfying two requirements: "the imaging half-life does not shorten with repeated administration" and "the imaging half-life does not change depending on whether or not the patient has anti-PEG antibodies."
[0059] 7. Tissue distribution of microbubbles under ABC phenomenon induction 7-1. Preparation method of DiR-modified PG(PEG)-MB DSPC:DSPG:DSPE-PEG(2k)-OMe = 1:2:0.33 (molar ratio) and DiR (1% relative to lipid molar concentration) were dissolved in an organic solvent mixture (chloroform:methanol:10% ammonia water:MilliQ = 65:35:4:4), and the organic solvent was removed under reduced pressure using a rotary evaporator to prepare a lipid thin film. After that, it was prepared in the same manner as above and used in the experiment.
[0060] 7-2.Preparation of DiR-modified nonPEG-MB DSPC:DSPG = 1:2 (molar ratio) and DiR (1% relative to lipid molar concentration) were dissolved in an organic solvent mixture (chloroform:methanol:10% ammonia water:MilliQ = 65:35:4:4), and the organic solvent was removed under reduced pressure using a rotary evaporator to prepare a lipid thin film. After that, it was prepared in the same manner as above and used in the experiment.
[0061] 7-3. Method for evaluating tissue distribution of each MB using IVIS ddY mice (female, 6 weeks old) fed a nonfluorescent diet were injected with PG(PEG)-MB (0.25 × 10 7 PEG-modified PG(PEG)-MB or DiR-modified non-PEG-MB were administered intravenously to induce anti-PEG antibodies. Seven days later, 1 × 10 9 [photons / sec] / [μW / cm 2 ] / Mice were administered intravenously under anesthesia, and 3 minutes after administration, blood was removed and each organ was excised. The excised organs were photographed using an In Vivo Imaging System (IVIS), and an ROI was drawn around each organ to measure the Total Radiant Efficiency [photons / sec] / [μW / cm 2 The distribution of MB in each tissue was evaluated using the index of [MB / mg tissue].
[0062] 7-4. Results of the study In the ABC phenomenon in liposomes, the pharmacokinetics of the drug changes dramatically between the first administration and readministration. Therefore, analysis of the tissue distribution of MB is important for elucidating the mechanism of the ABC phenomenon of MB. Therefore, we examined the tissue distribution of MB in mice with ABC phenomenon induction. In this study, PG(PEG)-MB labeled with the fluorescent substance DiR (DiR-modified PG(PEG)-MB) or nonPEG-MB labeled with DiR (DiR-modified nonPEG-MB) was administered to mice, and the organs were removed 3 minutes later, and the tissue distribution of MB was analyzed by IVIS. As a result, strong fluorescence was observed in the liver in the images taken with either MB (Figure 18), and it was revealed that the amount of fluorescence was distributed mainly in the liver, spleen, and lungs. Furthermore, from the results of the tissue distribution of MB during ABC phenomenon induction, the fluorescence intensity in the liver was similar in the ABC phenomenon induction group and the non-induction group in the DiR-modified nonPEG-MB. On the other hand, it was revealed that the fluorescence intensity in the liver of the ABC induction group was about 1.7 times higher than that of the non-induction group in the DiR-modified PG(PEG)-MB. There was no significant difference in the distribution of MB in the spleen with or without the ABC phenomenon. This suggests that the rapid decrease in ultrasound contrast brightness in the ABC phenomenon of MB is due in part to the rapid uptake of MB into the liver. In addition, the difference in tissue distribution between PG(PEG)-MB and PEG-modified liposomes under ABC phenomenon induction may be due to the large difference in the original physical properties, such as particle size, between MB and liposomes. [Industrial Applicability]
[0063] It can be used for ultrasound imaging.
Claims
1. A microbubble preparation comprising a lipid coating and a gas enclosed in the cavity of the coating, which enables the avoidance of the accelerated blood clearance (ABC) phenomenon, The coating is a lipid composed of distearoylphosphatidylcholine (DSPC) and distearoylphosphatidylglycerol (DSPG), The gas contains at least one of perfluoropropane, perfluorobutane, perfluoropentane, and perfluorohexane, or a mixed gas thereof; A microbubble preparation, characterized in that the coating is a lipid formed from distearoylphosphatidylcholine (DSPC) and distearoylphosphatidylglycerol (DSPG) in a molar ratio of 1:
2.
2. 2. The microbubble formulation of claim 1, wherein the gas is perfluoropropane.
3. The microbubble preparation according to claim 1 or 2, having a diameter of 10 nm to 5 μm.
4. The lipid surface of the coating is modified with a ligand; The microbubble formulation for theranostics according to claim 3, characterized in that the ligand is an arginine-glycine-aspartic acid (RGD) sequence peptide, transferrin, folic acid, hyaluronic acid, galactose or mannose.
Citation Information
Patent Citations
Ultrasound contrast agent and its manufacturing method
JP2006520754A
